Forest Laboratories And Nycomed Receive Complete Response Letter For Roflumilast

Published May 18, 2010

Forest Laboratories And Nycomed Receive Complete Response Letter For Roflumilast
Forest Laboratories, Inc. (NYSE: FRX) and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast.